2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
22
Lung Neoplasms
9
Lymphoma, Large-Cell, Anaplastic
4
Carcinoma
4
Carcinoma, Squamous Cell
2
Carcinoma, Large Cell
2
Brain Neoplasms
2
Adenocarcinoma
2
ALK-positive Advanced NSCLC
2
Sexual Dysfunction, Physiological
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Meningioma
1
Granuloma, Plasma Cell
1
Gastrointestinal Neoplasms
1
Eunuchism
1
Erectile Dysfunction
1
Ependymoma
1
Disease Progression
1
Carcinoma, Pancreatic Ductal
1
Breast Neoplasms
1
ALK-positive NSCLC
1
ALK+ Advanced NSCLC
1
Interventions
Oxaliplatin
29
Fluorouracil
25
Leucovorin
20
Capecitabine
18
Irinotecan
17
Surveys and Questionnaires
16
Bevacizumab
14
Cisplatin
12
Blood Specimen Collection
11
Drug Therapy
10
Standard of Care
9
Nivolumab
9
Gemcitabine
9
Cetuximab
7
pembrolizumab
6
Specimen Handling
6
S 1 (combination)
6
Endoscopic Mucosal Resection
6
Cyclophosphamide
6
atezolizumab
5
Sunitinib
5
Radiotherapy
5
Folfox protocol
5
Educational Status
5
Docetaxel
5
fludarabine
4
aldesleukin
4
Radiosurgery
4
Pemetrexed
4
Magnetic Resonance Spectroscopy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
brigatinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled